Adipotide

What is Adipotide?

Adipotide, also known as FTPP or prohibitin-targeting peptide, is an experimental peptide designed to kill the blood vessels that feed fat tissue. It was created by cancer researchers at the University of Texas MD Anderson Cancer Center, who had used the same strategy to target tumor blood vessels and then adapted it to fat.

Its best-known study, published in 2011, tested it in obese monkeys and reported rapid weight loss alongside changes in kidney function.⁵ It has never been approved for any use. It is still sold online as a research peptide and marketed to people seeking fast fat loss.

This page is direct about one thing. Adipotide does not work by changing appetite or metabolism in a gentle way. It works by destroying tissue, and its known side effects include kidney injury. That puts it in a different risk category from most compounds in this directory.

The concept behind it, called vascular targeting, came from the observation that blood vessels in different tissues carry different surface markers. By screening large libraries of peptides, researchers found sequences that home to specific tissues. Adipotide was the fat-targeting version of that idea.

How Adipotide works

Fat tissue, like any tissue, needs a blood supply. Adipotide has two parts. One part acts like a homing beacon that sticks to a protein found on the inner lining of blood vessels inside white fat. The other part is a toxic payload that, once inside those cells, makes them self-destruct. With their blood supply cut off, fat cells shrink and die, and the body reabsorbs the fat.

In detail, adipotide is a peptidomimetic with the sequence CKGGRAKDC-GG-(D)(KLAKLAK)2. The cyclic CKGGRAKDC motif binds prohibitin on the endothelium of white adipose tissue vasculature. The (KLAKLAK)2 domain is a proapoptotic sequence that disrupts mitochondrial membranes after internalization and triggers apoptosis of the targeted endothelial cells.⁵ Prohibitin is a cell-cycle regulating protein that is also overexpressed in some tumors, which is part of why the targeting strategy began in cancer research.⁴

What the research shows on Adipotide

The core evidence is a single primate study. Researchers treated obese Old World monkeys from three species with adipotide. Treatment induced targeted cell death inside the blood vessels of white fat, produced rapid weight loss, and improved insulin resistance. Imaging confirmed a marked loss of white fat.⁵

At the doses the researchers judged optimal, the monkeys also showed predictable changes in the function of the kidney's proximal tubules, the part of the kidney that reabsorbs water and salts. The authors described these changes as reversible.⁵ Even so, a kidney signal at effective doses is a serious finding for a drug intended for long-term use in people with obesity, many of whom already have kidney risk from diabetes or high blood pressure.

The study also drew a published challenge. A critic argued that the weight loss might reflect the monkeys simply eating less, a direct effect on food intake, rather than the proposed fat-vessel mechanism.⁷ That matters because it questions whether the targeting is as selective as claimed.

Rodent studies preceded the primate work, but there are no published human efficacy or safety results. The primate study was small by clinical standards, and it was not designed to answer long-term safety questions.

It is also worth noting what the monkey data do not show. They do not show how long the weight loss lasts after treatment stops, whether fat returns, or how the body handles repeated courses. Those are the questions any obesity drug must answer, and adipotide has not answered them.

Studied for: Obesity research.

Adipotide reference data

Adipotide dosage in published research

How Adipotide is used in practice

There is no medical use of adipotide. It is not prescribed by doctors, not offered by legitimate telehealth services, and not available from US compounding pharmacies. It appears on research-chemical websites as lyophilized powder in vials, often marketed with before-and-after claims drawn loosely from the monkey study. Doses suggested by sellers are extrapolated from animal work, a step that is unreliable for any drug and especially risky for one designed to destroy tissue.

Buyers face the usual gray-market problems: unverified identity, unknown purity, possible bacterial contamination and no dosing guidance grounded in human data. With adipotide those problems carry higher stakes, because the intended effect is to kill cells. A product that is mislabeled, overdosed or contaminated could cause harm that is hard to reverse.

Adipotide risks and side effects

Kidney injury is the main known risk. The primate study found dose-related changes in kidney tubule function at the doses that produced weight loss.⁵ Anyone with existing kidney disease, dehydration, or who takes drugs that stress the kidneys, such as NSAIDs or certain antibiotics, would face added risk.

Dehydration, reduced appetite and injection-site reactions have also been reported. The proapoptotic part of the peptide is not selective on its own. If the homing sequence binds other vessels or the peptide is degraded in ways that free the payload, other tissues could be damaged. No one has studied effects on pregnancy, fertility, the heart or the liver in people. Long-term consequences of repeatedly destroying blood vessels in fat tissue are unknown.

There is also the question of where the destroyed tissue goes and what replaces it. That has not been studied in humans.

Reported side effects

Alternatives to Adipotide

Several FDA-approved medicines produce substantial, sustained weight loss with known safety profiles. These include semaglutide (Wegovy), tirzepatide (Zepbound) and liraglutide (Saxenda), as well as phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave) and orlistat. For people with severe obesity, bariatric surgery has the longest track record. Each option involves trade-offs, but all have been tested in large human trials.

For people focused on a specific fat area rather than overall weight, procedures such as liposuction or cryolipolysis are regulated and their risks are documented.

Questions for a clinician

• What evidence applies to my situation, and at what level?
• What established alternatives should I consider first?
• What monitoring would be necessary, and how often?
• Can this be prescribed at all where I live, or only sold for research?